{"id":70819,"date":"2026-07-28T18:53:47","date_gmt":"2026-07-28T10:53:47","guid":{"rendered":"https:\/\/flcube.com\/?p=70819"},"modified":"2026-07-28T18:53:48","modified_gmt":"2026-07-28T10:53:48","slug":"china-medical-systems-rxilient-secures-exclusive-southeast-asia-rights-to-polichems-finjuve-and-ciclopoli-dermatology-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70819","title":{"rendered":"China Medical System&#8217;s Rxilient Secures Exclusive Southeast Asia Rights to Polichem&#8217;s Finjuve and Ciclopoli Dermatology Portfolio"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>China Medical System Holdings Limited<\/strong> (CMS) (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/0867:HKG\">HKG: 0867<\/a>) announced that its <strong>Southeast Asia subsidiary, Rxilient Medical Pte. Ltd.<\/strong> (&#8220;Rxilient&#8221;), has entered into a <strong>strategic collaboration<\/strong> with <strong>Polichem S.A.<\/strong>, a subsidiary of <strong>Almirall S.A.<\/strong>, to secure <strong>exclusive commercialization rights<\/strong> to two innovative dermatology products\u2014<strong>Finjuve<\/strong> (topical finasteride spray) and <strong>Ciclopoli<\/strong> (ciclopirox nail polish)\u2014across <strong>Southeast Asian and Greater China markets<\/strong>. The deal positions CMS to address significant unmet needs in hair loss and fungal nail infection treatment across high-growth Asian markets.<\/p>\n\n\n\n<h2 id=\"h-deal-overview\" class=\"wp-block-heading\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Indication<\/th><th>Territory<\/th><th>Exclusivity<\/th><\/tr><\/thead><tbody><tr><td><strong>Finjuve<\/strong><\/td><td>Androgenetic alopecia<\/td><td>Singapore, Malaysia, Philippines, Thailand, Indonesia<\/td><td>Exclusive commercialization<\/td><\/tr><tr><td><strong>Ciclopoli<\/strong><\/td><td>Mild-to-moderate onychomycosis<\/td><td>Hong Kong SAR, Macao SAR, Taiwan region, 11 Southeast Asian countries<\/td><td>Exclusive distribution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profiles-amp-clinical-differentiation\" class=\"wp-block-heading\">Product Profiles &amp; Clinical Differentiation<\/h2>\n\n\n\n<h3 id=\"h-finjuve-topical-finasteride-spray\" class=\"wp-block-heading\">Finjuve \u2013 Topical Finasteride Spray<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation:<\/strong> World&#8217;s first and only approved topical finasteride formulation for androgenetic alopecia<\/li>\n\n\n\n<li><strong>Efficacy:<\/strong> Comparable to oral finasteride in hair regrowth outcomes<\/li>\n\n\n\n<li><strong>Safety Advantage:<\/strong> <strong>100x lower systemic exposure<\/strong> compared to oral formulation<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Reduced impact on serum DHT levels while maintaining local efficacy<\/li>\n\n\n\n<li><strong>Patient Benefit:<\/strong> Effective hair loss treatment with significantly lower risk profile than systemic therapy<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-ciclopoli-ciclopirox-nail-polish\" class=\"wp-block-heading\">Ciclopoli \u2013 Ciclopirox Nail Polish<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Ingredient:<\/strong> Ciclopirox (antifungal agent)<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Mild-to-moderate onychomycosis (fungal nail infections) not involving nail matrix<\/li>\n\n\n\n<li><strong>Technology:<\/strong> Patented <strong>HPCH water-soluble nail-penetrating technology<\/strong><\/li>\n\n\n\n<li><strong>User Convenience:<\/strong> Eliminates need for nail filing or organic solvent film removal<\/li>\n\n\n\n<li><strong>Therapeutic Profile:<\/strong> Combines good efficacy, safety, and ease of use for chronic nail conditions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dermatology Market Opportunity:<\/strong> Southeast Asia&#8217;s dermatology market projected to grow at <strong>8-10% CAGR<\/strong> through 2030, driven by rising disposable income and aesthetic medicine adoption<\/li>\n\n\n\n<li><strong>Hair Loss Treatment Gap:<\/strong> Addresses significant unmet need in Asian markets where <strong>androgenetic alopecia affects 20-30% of adult males<\/strong>, but treatment options remain limited<\/li>\n\n\n\n<li><strong>Fungal Nail Infection Burden:<\/strong> Onychomycosis prevalence exceeds <strong>10% in tropical Southeast Asian climates<\/strong>, creating substantial market demand for effective topical solutions<\/li>\n\n\n\n<li><strong>CMS Regional Strategy:<\/strong> Leverages Rxilient&#8217;s established commercial infrastructure across Southeast Asia to rapidly deploy premium dermatology products<\/li>\n\n\n\n<li><strong>Competitive Advantages:<\/strong><\/li>\n\n\n\n<li><strong>First-mover status<\/strong> for topical finasteride in key Asian markets<\/li>\n\n\n\n<li><strong>Proprietary delivery technologies<\/strong> create barriers to generic competition<\/li>\n\n\n\n<li><strong>Premium pricing potential<\/strong> for innovative formulations addressing safety concerns<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Expands CMS beyond traditional pharmaceuticals into high-margin aesthetic and lifestyle dermatology segments<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-timeline-amp-next-steps\" class=\"wp-block-heading\">Commercial Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Pathway:<\/strong> Leveraging existing approvals from European markets to accelerate registration in Asian territories<\/li>\n\n\n\n<li><strong>Market Launch:<\/strong> Staged rollout beginning Q1 2027 in initial priority markets<\/li>\n\n\n\n<li><strong>Commercial Infrastructure:<\/strong> Utilizing Rxilient&#8217;s existing sales force and distribution network across 14 Asian territories<\/li>\n\n\n\n<li><strong>Marketing Strategy:<\/strong> Focus on dermatologist education and direct-to-consumer awareness campaigns for aesthetic indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial launches, market penetration, and revenue expectations for Finjuve and Ciclopoli. Actual results may differ due to risks including regulatory approvals, competitive dynamics, market acceptance, and reimbursement challenges in diverse Asian healthcare systems.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[325,844,4489],"class_list":["post-70819","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-china-medical-system","tag-hkg-0867","tag-rxilient-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Medical System&#039;s Rxilient Secures Exclusive Southeast Asia Rights to Polichem&#039;s Finjuve and Ciclopoli Dermatology Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient Medical Pte. Ltd. (&quot;Rxilient&quot;), has entered into a strategic collaboration with Polichem S.A., a subsidiary of Almirall S.A., to secure exclusive commercialization rights to two innovative dermatology products\u2014Finjuve (topical finasteride spray) and Ciclopoli (ciclopirox nail polish)\u2014across Southeast Asian and Greater China markets. The deal positions CMS to address significant unmet needs in hair loss and fungal nail infection treatment across high-growth Asian markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70819\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Medical System&#039;s Rxilient Secures Exclusive Southeast Asia Rights to Polichem&#039;s Finjuve and Ciclopoli Dermatology Portfolio\" \/>\n<meta property=\"og:description\" content=\"China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient Medical Pte. Ltd. (&quot;Rxilient&quot;), has entered into a strategic collaboration with Polichem S.A., a subsidiary of Almirall S.A., to secure exclusive commercialization rights to two innovative dermatology products\u2014Finjuve (topical finasteride spray) and Ciclopoli (ciclopirox nail polish)\u2014across Southeast Asian and Greater China markets. The deal positions CMS to address significant unmet needs in hair loss and fungal nail infection treatment across high-growth Asian markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70819\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T10:53:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-28T10:53:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70819#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70819\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Medical System&#8217;s Rxilient Secures Exclusive Southeast Asia Rights to Polichem&#8217;s Finjuve and Ciclopoli Dermatology Portfolio\",\"datePublished\":\"2026-07-28T10:53:47+00:00\",\"dateModified\":\"2026-07-28T10:53:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70819\"},\"wordCount\":482,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Medical System\",\"HKG: 0867\",\"Rxilient Medical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70819#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70819\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70819\",\"name\":\"China Medical System's Rxilient Secures Exclusive Southeast Asia Rights to Polichem's Finjuve and Ciclopoli Dermatology Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-28T10:53:47+00:00\",\"dateModified\":\"2026-07-28T10:53:48+00:00\",\"description\":\"China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient Medical Pte. Ltd. (\\\"Rxilient\\\"), has entered into a strategic collaboration with Polichem S.A., a subsidiary of Almirall S.A., to secure exclusive commercialization rights to two innovative dermatology products\u2014Finjuve (topical finasteride spray) and Ciclopoli (ciclopirox nail polish)\u2014across Southeast Asian and Greater China markets. The deal positions CMS to address significant unmet needs in hair loss and fungal nail infection treatment across high-growth Asian markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70819#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70819\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70819#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Medical System&#8217;s Rxilient Secures Exclusive Southeast Asia Rights to Polichem&#8217;s Finjuve and Ciclopoli Dermatology Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Medical System's Rxilient Secures Exclusive Southeast Asia Rights to Polichem's Finjuve and Ciclopoli Dermatology Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient Medical Pte. Ltd. (\"Rxilient\"), has entered into a strategic collaboration with Polichem S.A., a subsidiary of Almirall S.A., to secure exclusive commercialization rights to two innovative dermatology products\u2014Finjuve (topical finasteride spray) and Ciclopoli (ciclopirox nail polish)\u2014across Southeast Asian and Greater China markets. The deal positions CMS to address significant unmet needs in hair loss and fungal nail infection treatment across high-growth Asian markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70819","og_locale":"en_US","og_type":"article","og_title":"China Medical System's Rxilient Secures Exclusive Southeast Asia Rights to Polichem's Finjuve and Ciclopoli Dermatology Portfolio","og_description":"China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient Medical Pte. Ltd. (\"Rxilient\"), has entered into a strategic collaboration with Polichem S.A., a subsidiary of Almirall S.A., to secure exclusive commercialization rights to two innovative dermatology products\u2014Finjuve (topical finasteride spray) and Ciclopoli (ciclopirox nail polish)\u2014across Southeast Asian and Greater China markets. The deal positions CMS to address significant unmet needs in hair loss and fungal nail infection treatment across high-growth Asian markets.","og_url":"https:\/\/flcube.com\/?p=70819","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-28T10:53:47+00:00","article_modified_time":"2026-07-28T10:53:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70819#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70819"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Medical System&#8217;s Rxilient Secures Exclusive Southeast Asia Rights to Polichem&#8217;s Finjuve and Ciclopoli Dermatology Portfolio","datePublished":"2026-07-28T10:53:47+00:00","dateModified":"2026-07-28T10:53:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70819"},"wordCount":482,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Medical System","HKG: 0867","Rxilient Medical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70819#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70819","url":"https:\/\/flcube.com\/?p=70819","name":"China Medical System's Rxilient Secures Exclusive Southeast Asia Rights to Polichem's Finjuve and Ciclopoli Dermatology Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-28T10:53:47+00:00","dateModified":"2026-07-28T10:53:48+00:00","description":"China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient Medical Pte. Ltd. (\"Rxilient\"), has entered into a strategic collaboration with Polichem S.A., a subsidiary of Almirall S.A., to secure exclusive commercialization rights to two innovative dermatology products\u2014Finjuve (topical finasteride spray) and Ciclopoli (ciclopirox nail polish)\u2014across Southeast Asian and Greater China markets. The deal positions CMS to address significant unmet needs in hair loss and fungal nail infection treatment across high-growth Asian markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70819#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70819"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70819#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Medical System&#8217;s Rxilient Secures Exclusive Southeast Asia Rights to Polichem&#8217;s Finjuve and Ciclopoli Dermatology Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70819"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70819\/revisions"}],"predecessor-version":[{"id":70821,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70819\/revisions\/70821"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}